| abstract |
Disclosed is a biomarker protein whose change in concentration or activity level is associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with complement inhibitors. Compositions and methods for investigating the concentration and / or activity of one or more of the biomarker proteins in a biological fluid are also provided. The composition and method, among other things, to assess the risk of developing aHUS, to diagnose aHUS, to determine whether a subject is experiencing the first acute symptoms of aHUS, And / or to monitor response to treatment with a complement inhibitor or to optimize such treatment. [Selection figure] None |